DOCSLIB.ORG

Cannabis Indica

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Indica Basic Information of Cannabis Chatchada Bodhibukkana, Ph.D. R&D Institute, GPO Plant Type sativa indica ruderalis Ref : https://smoke.io/strains/@jwolf/the-clear-difference-between-cannabis-sativa-indica-and-ruderalis-or-simple-photos2 Plant Type - Origin Sativa Indica Ruderalis Tropical zone, which is The dry regions with little rainfall; The Asian parts of Russia. characterized by its warm and Afghanistan, Lebanon, and the Difference in daylengths. humid climate. Hindu Kush. (approx. 19 hours of daylight in It is located 23.5 degrees above Central Asia summer & 10.5 hours of daylight and below the equator. in winter) Small difference in daylengths. (approx. 13.5 hours of daylight in Short vegetative phase (growth summer & 10.5 hours of daylight phase). in winter) Automatically switches to the flowering phase (floral phase) regardless of the season. Ref : https://www.mallorca-seeds.com/difference-sativa-indica-ruderalis/ 3 Plant Type - Origin สายพันธ์ไทย-> sativa Ref : https://smoke.io/strains/@jwolf/the-clear-difference-between-cannabis-sativa-indica-and-ruderalis-or-simple-photos4 Sativa Vs Indica Ref: https://wisetoast.com/types-of-marijuana-and-effects Ref : https://www.cannaconnection.com/blog/11392-difference-indica-sativa-ruderalis-hybrid-plants 5 Ref : https://www.amazon.com/Periodic-Table-Cannabis-Poster-Print/dp/B00MBI4HVM Cannabis Plant Anatomy Sinsemilla “without seeds” Trichomes Ref : https://herbology.org/2019/08/14/cannabis-anatomy-the-parts-of-the-plant/ Male Female Hermaphroditic Pollen sac Stigma Pollen sac + Stigma Ref : https://www.amsterdamgenetics.com/spot-male-female-hermaphrodite-cannabis/ Non cannabinoids • Terpenes • Sugars • Flavonoids • Fats • Chlorophyll • Lignin • Pigments • Starches • Waxes • Celluloses • Pectins • Etc. Ref : https://www.royalqueenseeds.com/blog-what-are-cannabis-flavonoids-and-what- Ref : https://www.nature.com/articles/d42473-018-00066-4 do-they-do-n799 D 9-THC D 8-THC CBN CBC CBG CBD Chemical structures of compounds isolated from Cannabis sativa organized via family substructure. Ref : Husni et.al, 2014 Examples of Terpenes in Cannabis α-Pinene Δ3-Carene cis-Ocimene Humulene γ-Eudesmol β-Pinene α-Terpinene Terpinolene δ-Guaiene β-Eudesmol Myrcene β-Phellandrene β-Caryophyllene Elemene α-Phellandrene Limonene α-Guaiene Guaiol Ref : https://profofpot.com/terpene-content-cannabis/ Examples of Terpenes in Cannabis Ref : https://www.cannainsider.com/reviews/cannabis-terpenes/ Entourage Effect The Entourage effect is the synergistic benefit of whole- plant cannabis that contains a range of naturally occurring cannabinoids flavonoids and terpenes to maximize the potency, effectiveness, and therapeutic scope of cannabis. Ref : https://blog.funpot.ca/cbd-a-better-you-cbd-the-entourage-effect/ Ref : https://cannigma.com/treatment/what-is-the-entourage-effect/ เปรียบเทียบการปลูก 3 แบบ Outdoor Indoor Greenhouse 1.ต้นทุนต ่า 1.ต้นทุนสูงมาก 1.ต้นทุนต ่ากว่าระบบ Indoor 2.ผลผลิตไม่แน่นอนและไม่มีคุณภาพ 2.ผลผลิตมีคุณภาพสูง 2.ผลผลิตมีคุณภาพสูง 3.ปลูกได้ปีละรอบ 3.ปลูกได้ปีละสามรอบ 3.ปลูกได้ปีละสามรอบ 4.ใช้เกษตรกรทั วไป 4.ใช้บุคคลากรที มีความช่านาญ 4.ใช้เกษตรกรช่านาญการ 5.เสี ยงต่อโรคพืชและแมลง และอาจ เฉพาะมาก 5.อาจจะมีโรคพืชหรือแมลงได้ ปนเปื้อนโลหะหนัก 5.ไม่มีโรคพืช แมลง และโลหะหนัก 6.เป็นระบบที คุ้มค่าและเหมาะส่าหรับ ภูมิอากาศประเทศไทย 14 Cannabis sativa L. subsp. indica . • Glandular trichomes เป็นส่วนที่ ผลิต Cannabinoids และ terpenes • Glandular trichomes พบได้ทั่วทั้ง ต้น แต่จะมีปริมาณหนาแน่นที่สุด บริเวณช่อดอก • ช่อดอก จึงเป็นส่วนส าคัญที่ให้ สารส าคัญ Cannabinoids (THC, CBD) 4 5 3 QC of Finished Product 2 Formulation • Appearance QC of Extract • Identification 1 • Capsules 9 • • Content of -THC • Appearance Sublingual drops • Extraction • Content of CBD • Identification Oromucosal spray • Microbial limit tests QC of Raw Material 9 • Suppositories • Solvent extraction • Content of -THC • Other parameters •Appearance • Content of CBD • Topicals • Supercritical fluid • depend on dosage •Identification • Loss on drying Transdermal patches form extraction (CO2) • Inhalers •Foreign material • Short path • Microbial limit tests •Moisture content distillation •Microbial limit tests •Metal limits •Pesticide limits 1 Ethanol Extraction ( - 50 °C ) Cannabis flos 2 3 Medical Cannabis Extracts (Cannabinoids + Terpenoids + Flavonoids) Separation by Evaporation 17 18 SOLVENT EXTRACTION • PROS: SOLVENT Evaporating solvent • Inexpensive- This method doesn’t require any fancy machinery. • Simple • High yield • CONS: • Have to evaporate solvent as much as possible • Aware - overheated or overmixed Solvent/extract and also flammable solvent. mixture Ref : https://www.powerblanket.com/blog/cbd-extraction-methods/ CO2 EXTRACTION • PROS: • Safe when done by professionals- CO2 is used in countless food products and is perfectly safe for consumption • Yields high-quality • CONS: • Very expensive- setup costs start at approximately $40,000 • Not suitable for industry scale production Ref : https://www.powerblanket.com/blog/cbd-extraction-methods/ Oil Extraction • Pros: • Easy- This is by far the easiest extraction method and is a popular home option. OIL • Cons: • Low Yields- This method produces low yields of heavily diluted CBD. • Aware – toxicity of oils (ex. Naphtha) using in the extraction method Ref : https://www.powerblanket.com/blog/cbd-extraction-methods/ Physical and Chemical properties Chemical formula C21H30O2 C21H30O2 Molecular weight 314.46 314.46 Solubility in water 0.0126 mg/mL 0.0028 mg/mL Solubility in ethanol 23.6 mg/mL Soluble (1:1) log P 6.1 6.93 Physical and Chemical properties Instability • Oxidation products derived from fatty acid degradation during the storage period of macerated oils are critical for overall formulation stability. • Exposure to light was shown to be the greatest single factors in loss of cannabinoids especially in solutions. Pharmacokinetics of Cannabis preparations • นอกจากข้อมูลด้านเภสัชวิทยา การจัดตั้งสูตรต่ารับสารสกัดกัญชา (Cannabis oil) ต้องพิจารณาถึง Physical & chemical properties รวมทั้ง Pharmacokinetic ของสารสกัดเพื อพัฒนาสูตรต่ารับที เหมาะสม มีคุณภาพ ประสิทธิภาพ ความปลอดภัย และตรงตามความต้องการของผู้ป่วย • เนื องจากการการได้รับ Cannabinoids รูปแบบรับประทาน ให้ค่าชีวปริมาณออกฤทธิ์ (bioavailability) ต ่า จากการผ่าน First-pass metabolism ดังนั้นเพื อเพิ มการน่าส่งยาเข้าร่างกาย จึงมีการพัฒนาสูตรต่ารับในรูปแบบอื นในการน่าส่งยา เช่น Sublingual, Vaporization of product and inhalation และ Rectal administration Cannabis preparations • Pharmaceutical preparations • CBD • THC • THC/CBD • Synthetic cannabinoids • Other preparations • Food supplements/ Cosmetics Pet products Cannabis oil - THC Cosmetics - CBD Drugs Cannabis - THC/CBD products Synthetic cannabinoids - Nabilone Supplements Foods/ Drinks - Dronabinol Ref : https://bedrocan.com/wp-content/uploads/a-primer-to-medicinal-cannabis_lr.pdf Approved Drugs Pharmaceutical preparations (Phytocannabinoids) EPIDIOLEX ® : Oral solutions USFDA approve : 2018 รักษาโรคลมชักในผู้ป่วยอายุ 2 ปีขึ้นไป Contains : CBD 100 mg/mL Dosage : เริ มให้ที 2.5 mg/kg วันละ 2 ครั้ง (5 mg/kg/day) หลังจากได้รับยา 1 สัปดาห์สามาถเพิ มได้ถึง 5 mg/kg วันละ 2 ครั้ง (10 mg/kg/day) Indication : seizures associated with Lennox-Gastaut syndrome or Dravet syndrome ในผู้ป่วยอายุ 2 ปีขึ้นไป Common side effects : sleepiness, decreased appetite, diarrhea, increase in liver enzymes, feeling very tired and weak, rash, sleep problems, and infections. • In an August 2018 call with investors, GW Pharmaceuticals revealed the price of Epidiolex would cost roughly $32,500 per patient, per year. Pharmaceutical preparations (Phytocannabinoids) SATIVEX® : Oromucosal spays UK Approve : 2010 รักษาภาวะกล้ามเนื้อหดเกร็ง เนื องมากจากโรค Each 100 microliter spray contains: ปลอกประสาทเสื อมแข็ง (MS) 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). Dosage : ค่อยๆ เพิ มปริมาณสเปรย์ 1 สเปรย์ต่อวัน มากสูงสุดถึง 12 สเปรย์ต่อวัน Indication : Add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). Common side effects : palpitations (1.2%), tooth discolouration (2.1%), oral mucosal disorder (2.2% ) Pharmaceutical preparations (Synthetic cannabinoids) CESAMET® : Capsules USFDA Approve : 1985 รักษาอาการคลื นไส้อาเจียนจากการใช้เคมีบ่าบัดใน Contains : 1 mg (2.7 µmol) Nabilone per cap การรักษามะเร็ง และไม่ตอบสนองต่อยาต้านอาการ คลื นไส้อาเจียนตัวอื น Dosage : ในผู้ใหญ่รับประมาณครั้งละ 1 หรือ 2 mg วันละ 2 ครั้ง สูงสุดไม่เกิน 6 mg แบ่งให้วันละ 3 ครั้ง Indication : for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments Common side effects : drowsiness, vertigo, dry mouth, euphoria (feeling “high”), ataxia, headache, and concentration difficulties. Pharmaceutical preparations (Synthetic cannabinoids) MARINOL® : Capsules USFDA Approve : 1985 1. การเบื ออาหาร น้่าหนักลดในผู้ป่วยเอดส์ Contains : 2.5 mg, 5 mg, 10 mg Dronabinol per cap 2. รักษาอาการคลื นไส้อาเจียนจากการใช้เคมี Dosage : บ่าบัดในการรักษามะเร็ง ขนาดแนะน่าเริ มให้รับประทานครั้งละ 2.5 mg วันละ 2 ครั้ง ก่อนอาหารกลางวัน และอาหารเย็น 1 ชั วโมง Indication : 1. Anorexia associated with weight loss in patients with AIDS. 2. Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Common side effects : abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, thinking abnormal and vomiting. Unapproved Drugs Cannabis preparations • Pharmaceutical
Load more

Recommended publications
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • 15.04.610.270 - Marijuana/Cannabis Commercial Uses
    15.04.610.270 - Marijuana/Cannabis Commercial Uses. Commercial Cannabis activities, including but not limited to cultivation, manufacturing, testing, distribution, and retail are subject to the standards and procedures of the Municipal Code, State Law, and the regulations set forth in these Zoning Regulations. A. Applicability. These standards apply to all establishments that are involved in any commercial cannabis activity. B. Definitions1 []. The following words or phrases, whenever used in this section, have the following definitions: 1. A-license. A State license issued for cannabis or cannabis products that are intended for adults 21 years of age and over and who do not possess physician's recommendations. 2. Attending Physician. An individual who possesses a license in good standing to practice medicine or osteopathy issued by the Medical Board of California or the Osteopathic Medical Board of California and who has taken responsibility for an aspect of the medical care, treatment, diagnosis, counseling, or referral of a patient and who has conducted a medical examination of that patient before recording in the patient's medical record the physician's assessment of whether the patient has a serious medical condition and whether the medical use of cannabis is appropriate. 3. Bureau of Cannabis Control ("the Bureau"). The bureau within the California Department of Consumer Affairs created to develop, administer and enforce comprehensive rules for medicinal and adult-use cannabis in California. The Bureau is responsible for the regulation and licensing of all commercial cannabis retail, distribution, testing, microbusinesses and temporary cannabis events in California. 4. California Department of Food and Agriculture — CalCannabis Cultivation Licensing ("the CDFA").
    [Show full text]
  • The Entourage Effect of Whole-Plant Medicine
    CANN BIS THE ENTOURAGE EFFECT OF Whole-Plant, WHOLE-PLANT MEDICINE Whole Medicine BY DEBORAH PARKER WONG ithin the last decade, scientists have dis- as well as the less-known such as CBDV, a proven covered hundreds of biologically active anti-epileptic. W nutrients called phytochemicals, which are Food and health researchers have long concluded found in whole, unprocessed foods. There’s pteros- that while our bodies readily absorb these kinds of tilbene, a powerful antioxidant found in almonds, nutrients from whole foods, our ability to absorb syn- blueberries and Pinot Noir grapes that enables cells thetic, isolated supplements is limited at best. That’s exactly what cannabis researchers at the Hebrew University of Jerusalem discovered when comparing the efficacy of whole-plant cannabinoid (CBD) ex- tracts with synthetic, single-molecule CBDs. As the pharmaceutical industry rushes to market synthetic CBDs, research points to what’s called the “Entourage Effect,” wherein compounds work- ing together synergistically in whole-plant medi- cines amplify the overall effects and benefits of the medicine. When comparing synthetic CBDs with whole-plant extract, the Israeli researchers ob- served a narrow therapeutic window that limits the to break down fat and cholesterol; compounds like usefulness of the synthetic form and a far greater lycopene, which colors tomatoes red, and antho- range of effectiveness for CBD-rich, whole-plant cycanin, which gives berries of all kinds their deep extract. This, combined with the Entourage Effect, hues of blue. And of course, there’s the exciting makes whole-plant CBD extracts more effective at world of phytocannabinoids, cannabis-derived com- lower doses, with fewer adverse side effects, mak- pounds including the famously psychoactive THC, ing it ideal for clinical use.
    [Show full text]
  • Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model
    Glaucoma Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model Sally Miller,1 Emma Leishman,1 Sherry Shujung Hu,2 Alhasan Elghouche,1 Laura Daily,1 Natalia Murataeva,1 Heather Bradshaw,1 and Alex Straiker1 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States 2Department of Psychology, National Cheng Kung University, Tainan, Taiwan Correspondence: Alex Straiker, De- PURPOSE. Cannabinoids, such as D9-THC, act through an endogenous signaling system in the partment of Psychological and Brain vertebrate eye that reduces IOP via CB1 receptors. Endogenous cannabinoid (eCB) ligand, 2- Sciences, Indiana University, Bloom- arachidonoyl glycerol (2-AG), likewise activates CB1 and is metabolized by monoacylglycerol ington, IN 47405, USA; lipase (MAGL). We investigated ocular 2-AG and its regulation by MAGL and the therapeutic [email protected]. potential of harnessing eCBs to lower IOP. Submitted: February 16, 2016 Accepted: May 16, 2016 METHODS. We tested the effect of topical application of 2-AG and MAGL blockers in normotensive mice and examined changes in eCB-related lipid species in the eyes and spinal Citation: Miller S, Leishman E, Hu SS, cord of MAGL knockout (MAGLÀ/À) mice using high performance liquid chromatography/ et al. Harnessing the endocannabinoid tandem mass spectrometry (HPLC/MS/MS). We also examined the protein distribution of 2-arachidonoylglycerol to lower intra- ocular pressure in a murine model. MAGL in the mouse anterior chamber. Invest Ophthalmol Vis Sci. RESULTS. 2-Arachidonoyl glycerol reliably lowered IOP in a CB1- and concentration-dependent 2016;57:3287–3296. DOI:10.1167/ manner. Monoacylglycerol lipase is expressed prominently in nonpigmented ciliary iovs.16-19356 epithelium.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Marinol Cannabidiol C21H30O2 Trade Name
    Cannabinoids are a group of terpenophenolic compounds secreted by Cannabis flowers that provide relief from a wide array of symptoms including, pain, nausea, and inflammation. They operate by imitating the body’s natural endocannabinoids, which activate to maintain internal stability and overall health. When consumed, cannabinoids bind to receptor sites throughout the brain (CB1 receptors) and body (CB2 receptors). Different cannabinoids have different effects based on their binding affinity for each receptor. By targeting specific cannabinoids at these receptors, different types of relief can be achieved. Presently, there are at least 113 different cannabinoids isolated from Cannabis—each exhibiting varied effects. THC Tetrahydrocannabinol C21H30O2 Trade name: Marinol Legal Status: US – Schedule I, Schedule II (as Cesamet), Schedule III (as Marinol) OH CA – Schedule II UK – Class B AU – S8 (controlled) H Psychoactive Tetrahydrocannabinol (THC) is typically the most abundant cannabinoid present in cannabis products on the market today. THC has very high psychoactive characteristics and is associated with the ‘high’ and euphoria experienced when using cannabis products. When smoked or ingested, THC binds to cannabinoid receptors throughout the body and affects memory, O coordination, concentration, pleasure, and time perception. H Medicinal Benefits Analgesic • Anti-nauseant • Appetite Stimulant Reduces Glaucoma Symptoms Sleep Aid • Reduces Anxiety and PTSD Symptoms CBD Cannabidiol C21H30O2 Trade name: Epidiolex OH Legal Status: US – Schedule I CA – Schedule II UK – POM (Perscription only) H AU – S4 (Perscription only) non-psychoactive Cannabidiol (CBD) is a major phytocannabinoid and accounts for up to 40% of the plant’s extract. Due to its lack of psychoactivity and HO non-interference with motor and psychological functions, it is a leading candidate for a wide variety of medical applications.
    [Show full text]
  • Model Healthy Beverage Vending Agreement
    Butte County Public Health Department Note Because of limited data available on the safety of high potency Cannabis Products, the Butte County Public Health Department recommends that retailers not be allowed to carry Cannabis Products with THC content in excess of 20%. This is the one recommendation that is different from the original ordinance created by Public Health Institute. Authors Support - Lynn Silver, MD, MPH, Public Health Institute - Alisa Padon, PhD, Public Health Institute Contributors - Ted Mermin, JD - Leslie Zellers, JD - Immigrant Legal Resources Center - James Mosher, JD Getting it Right from the Start A project of the Public Health Institute 555 12th Street, Oakland, CA 94607 www.gettingitrightfromthestart.org Telephone: 510.285.5648 Fax: 510.285.5501 Email: [email protected] Acknowledgement This Model Ordinance was adapted in part from ChangeLab Solutions and the California Department of Public Health’s Model Tobacco Retail License Ordinance and “plug-ins,” which have been adopted by cities and counties across the State of California. We acknowledge and appreciate their important contributions, although they are not responsible for the content. We also thank the many individuals who contributed interview time and comments during the development process. Note The legal information provided in this model ordinance does not constitute legal advice or legal representation. For legal advice, readers should consult an attorney in their state. Table of Contents Introduction ......................................................................................................................
    [Show full text]
  • Safe Cannabis Sales Act of 2019
    1 2 ____________________________ 3 Chairman Phil Mendelson 4 at the request of the Mayor 5 A BILL 6 ______________________ 7 8 IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 9 10 _______________________________________ 11 Chairman Phil Mendelson, at the request of the Mayor, introduced the following bill, 12 which was referred to the Committee on ________________. 13 14 To amend Title 25 of the District of Columbia Official Code to establish the Alcoholic 15 Beverage and Cannabis Board and the Alcoholic Beverage and Cannabis 16 Administration; to establish that the Chairperson of the ABCA Board may also 17 have demonstrated knowledge in the cannabis industry; to define various terms 18 for new chapters 21 through 30; to prohibit the sale of cannabis or cannabis 19 products without a license; to provide the Board with the authority to issue 20 marijuana licenses for 3 year periods; to prohibit exchanges of marijuana for 21 purchasing another item; to create cultivation, manufacturer, distributor, off- 22 premises retailer, and testing facility license categories; to require the Board to 23 consider within 18 months new off-premises and on-premises retailer’s license 24 categories; to require laboratory agent registration with the ABCA; to require 25 persons volunteering or working at cultivation, manufacturer, distributor, and off- 26 premises retailers to obtain a worker’s license; to require off-premises retailers 27 and medical marijuana dispensaries to obtain a delivery endorsement from the 28 Board to deliver cannabis and cannabis products
    [Show full text]
  • Advantages of Polypharmaceutical Herbal Cannabis Compared to Single-Ingredient, Synthetic Tetrahydrocannabinol
    BIORESOURCE HEMP 2000, Wolfsburg 13.-16. September 2000, www.nova-institut.de PRESENTATION FOR NOVA-INSTITUTE “ONLINE PROCEEDINGS” Third International Symposium: Bioresource Hemp. 13-16 September 2000, Wolfsburg, Germany Advantages of polypharmaceutical herbal Cannabis compared to single-ingredient, synthetic tetrahydrocannabinol John McPartland Vermont Alternative Medicine/AMRITA 53 Washington Street Ext. Middlebury, VT 05753 USA Introduction In the United States, marijuana (Cannabis sativa, possibly also Cannabis indica and Cannabis afghanica) is classified by the Drug Enforcement Administration (DEA) as a prohibited Schedule I drug ("no currently accepted medical use"). As a substitute for marijuana, the DEA approved dronabinol (Marinol®). Dronabinol is synthetic delta-9-tetrahydrocannabinol (∆9-THC). It is formulated in a capsule, designed for oral administration. Because ∆9-THC is the primary psychoactive ingredient in both Dronabinol and marijuana, the DEA considers Dronabinol equal to marijuana in effectiveness, for the treatment of nausea, vomiting, and anorexia. But Dronabinol and marijuana are not equal, according to many reports (Grinspoon & Bakalar 1997). Many patients report that marijuana has better therapeutic activity than Dronabinol, and that marijuana has less side effects than Dronabinol. Dronabinol often causes psychological “overdose” reactions, symptoms such as dysphoria, depersonalization, anxiety, panic reactions, and paranoia. Route of administration These side effects may be secondary to the drug's route of administration — Dronabinol is formulated as a capsule for oral administration. Swallowing THC leads to first-pass metabolism by the liver, resulting in approximately equal amounts of THC and its 11-hydroxy metabolite in the blood stream (Perez-Reyes & Wall, 1981). The metabolite, 11-hydroxy-THC, is about 4 times more psychoactive www.biorohstoff-hanf.de - 1 - www.bioresource-hemp.de BIORESOURCE HEMP 2000, Wolfsburg 13.-16.
    [Show full text]
  • Pharmacodynamics of Cannabinoids
    Open Access Archives of Pharmacy and Pharmaceutical Sciences Review Article Pharmacodynamics of cannabinoids Alexandra Sulcova* ISSN ICCI - International Cannabis and Cannabinoids Institute, Jachymova 26/2, 110 00 Praha, 2639-992X Czech Republic “Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the *Address for Correspondence: Alexandra Sulcova, M.D, Ph.D, Professor of Pharmacology, living organism by interaction with its biochemical and biophysical functions up to the FCMA, FECNP, FCINP, ICCI - International cellular level) is studied for a long time during both, physiological and pathological Cannabis and Cannabinoids Institute, Jachymova conditions. Cannabinoids received their names according to their natural occurrence 26/2, 110 00 Praha, Czech Republic, Tel: 420 732167678; Email: [email protected] as constituents of Cannabis sativa L. (marijuana). The species was classiied in the “Linnaeus’s Species Plantarum (1753)”, the word “sativa” means things that are Submitted: 12 April 2019 Approved: 07 May 2019 cultivated [1]. For ages, people have used cannabis-based preparations for healing and Published: 08 May 2019 pain suppression until the discovery (in 1897) of aspirin (acetylsalicylic acid) which contemporary medicine uses until today. Chemical investigation of marijuana conirmed Copyright: © 2019 Sulcova A. This is an open access article distributed under the Creative various cannabinoid-type components called cannabinoids (presently estimated at Commons Attribution License, which permits about 150). Regarding their possible pharmacodynamic effects, tetrahydrocannabinol unrestricted use, distribution, and reproduction (THC) and cannabidiol (CBD) are the most explored. The determination of THC structure in any medium, provided the original work is properly cited by means of nuclear magnetic resonance imaging increased sharply the number of professional scientiic reports dealing with the studies of THC pharmacodynamic mechanisms of action [2].
    [Show full text]
  • Cannabis-Related Pharmaceutical Drugs
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 31 August 2020 Type of the Paper (Review) Cannabis-related pharmaceutical drugs Dvora Namdar1, Omer Anis2, Patrick Poulin3, Hinanit Koltai1,* 1 Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel; [email protected]; [email protected] 2 Department of Urology, Sheba Medical Center; [email protected] 3 Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Canada; [email protected] * Correspondence: [email protected]; Tel.: +972‐3‐9683039 (H.K.) Abstract: Despite the surge in the research of cannabis chemistry and its biological and medical activity, only a few cannabis‐based pharmaceutical‐grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)‐approved and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or analogs of phytocannabinoids (cannabinoids produced by the plant) may be developed into single‐molecule drugs. However, since in many cases treatment with whole plant extract is preferred over treatment with a single purified molecule, some more recently developed cannabis‐derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergy may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few or multiple molecules as drugs is a challenging process and certain considerations that should be reviewed in this process, including issues of drug‐drug interactions, are also discussed here.
    [Show full text]
  • Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report
    PNNL-27050 Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report November 2017 KM Branch EP Kennedy ME Lerchen* AC Dalton *Corresponding author Prepared for the U.S. Nuclear Regulatory Commission under an Interagency Agreement with the U.S. Department of Energy Contract DE-AC05-76RL01830 PNNL-27050 Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report KM Branch EP Kennedy ME Lerchen* AC Dalton *Corresponding author November 2017 Prepared for the U.S. Nuclear Regulatory Commission under an Interagency Agreement with the U.S. Department of Energy Contract DE-AC05-76RL01830 Pacific Northwest National Laboratory Richland, Washington 99352 PNNL-27050 ABSTRACT Studies clearly demonstrate that the use of marijuana (Cannabis sativa and other related Cannabis species and hybrids) and cannabinoids from other sources have negative impacts on an individual’s fitness to perform safety- or security-sensitive functions. The discovery of the endocannabinoid system (i.e., cannabinoid receptors, their location, and function within the human body) in the 1980s, and the subsequent characterization of that system provided a framework for examining the role and function of cannabinoids. That framework prompted an increase in research on the effects of substances that activate or inhibit the endocannabinoid system, including marijuana and synthetic cannabinoids, which led to a greater understanding of the potential benefits and adverse effects of such substances. This new understanding has heightened interest in the potential medical uses of cannabinoids, development of pharmaceutical cannabinoids, and re-examination of previous research on cannabinoid metabolism, elimination, and the relationship of effects to dose and time.
    [Show full text]